跳至主要内容
临床试验/NCT03731286
NCT03731286已完成不适用

A Double-Blind Randomized, Double-dummy, Placebo-controlled, Parallel-Group Study of the Long-term Safety and Efficacy of EnXtra (E-AG-01) in Healthy Adults

Vedic Lifesciences Pvt. Ltd.2 个研究点 分布在 1 个国家目标入组 60 人开始时间: 2018年11月23日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
60
试验地点
2
主要终点
Change in ECG from baseline to end of the treatment.

研究概览

简要总结

The present study has been proposed to investigate the long-term safety and efficacy of EnXtra in healthy adults habituated to caffeine.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Supportive Care
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 60 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • History of regular caffeine consumption.
  • Body mass index (BMI) of ≥18.5 and <25.00 kg/m
  • Fasting blood glucose < 126 mg/dl
  • Participants who are willing to complete all study procedures including study-related questionnaires and comply with study requirements.
  • Participants who are willing to abstain from use of any nutritional supplement and herbal preparation 48 hrs prior to study visit.

排除标准

  • Participants unable to abstain from caffeine-containing products for 12 hours prior to the site visit.
  • Known cases of type II Diabetes Mellitus.
  • Participants with uncontrolled hypertension (≥140/90 mm Hg), with or without anti-hypertensive medication.
  • Participants suffering from primary or secondary insomnia with/ without active treatment.

结局指标

主要结局

Change in ECG from baseline to end of the treatment.

时间窗: 84 Days

ECG parameters including PR interval, QRS duration, QT interval and RR interval will be evaluated from baseline and end of the treatment

次要结局

未报告次要终点

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验

A Long-term Safety and Efficacy of EnXtra (E-AG-01)... | 临床试验